Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine by Baras, Benoît et al.
Cross-Protection against Lethal H5N1 Challenge in
Ferrets with an Adjuvanted Pandemic Influenza Vaccine
Benoı ˆt Baras
1, Koert J. Stittelaar
2, James H. Simon
2, Robert J. M. M. Thoolen
3, Sally P. Mossman
1, Frank H. M. Pistoor
2, Geert van Amerongen
2,
Martine A. Wettendorff
1, Emmanuel Hanon
1, Albert D. M. E. Osterhaus
2,4*
1Preclinical Virology, GlaxoSmithKline Biologicals, Rixensart, Belgium, 2ViroClinics BV, Rotterdam, The Netherlands, 3Global Pathology Support,
Toxicologic Pathology, The Hague, The Netherlands, 4Department of Virology, Erasmus Medical Center (MC), Rotterdam, The Netherlands
Background. Unprecedented spread between birds and mammals of highly pathogenic avian influenza viruses (HPAI) of the
H5N1 subtype has resulted in hundreds of human infections with a high fatality rate. This has highlighted the urgent need for
the development of H5N1 vaccines that can be produced rapidly and in sufficient quantities. Potential pandemic inactivated
vaccines will ideally induce substantial intra-subtypic cross-protection in humans to warrant the option of use, either prior to
or just after the start of a pandemic outbreak. In the present study, we evaluated a split H5N1 A/H5N1/Vietnam/1194/04, clade
1 candidate vaccine, adjuvanted with a proprietary oil-in- water emulsion based Adjuvant System proven to be well-tolerated
and highly immunogenic in the human (Leroux-Roels et al. (2007) The Lancet 370:580–589), for its ability to induce intra-
subtypic cross-protection against clade 2 H5N1/A/Indonesia/5/05 challenge in ferrets. Methodology and Principal Findings.
All ferrets in control groups receiving non-adjuvanted vaccine or adjuvant alone failed to develop specific or cross-reactive
neutralizing antibodies and all died or had to be euthanized within four days of virus challenge. Two doses of adjuvanted split
H5N1 vaccine containing $1.7 mg HA induced neutralizing antibodies in the majority of ferrets to both clade 1 (17/23 (74%)
responders) and clade 2 viruses (14/23 (61%) responders), and 96% (22/23) of vaccinees survived the lethal challenge.
Furthermore lung virus loads and viral shedding in the upper respiratory tract were reduced in vaccinated animals relative to
controls suggesting that vaccination might also confer a reduced risk of viral transmission. Conclusion. These protection data
in a stringent challenge model in association with an excellent clinical profile highlight the potential of this adjuvanted H5N1
candidate vaccine as an effective tool in pandemic preparedness.
Citation: Baras B, Stittelaar KJ, Simon JH, Thoolen RJMM, Mossman SP, et al (2008) Cross-Protection against Lethal H5N1 Challenge in Ferrets with an
Adjuvanted Pandemic Influenza Vaccine. PLoS ONE 3(1): e1401. doi:10.1371/journal.pone.0001401
INTRODUCTION
Influenza pandemics occurring over the past centuries have cost the
lives of many millions of people. The unprecedented spread of the
highly pathogenic avian influenza virus (HPAI) of the H5N1 subtype
among birds and mammals in the past decade and hundreds of
reported zoonotic transmissions with a high case fatality rate,
emphasised the need for worldwide pandemic preparedness [1–3].
The timely availability of a safe and effective pandemic vaccine will
play a crucial role in efforts to combat this pandemic threat [4–6].
Mathematical modelling has demonstrated that the use of a pre-
pandemic vaccine before or soon after the onset of a pandemic, in
combination with other protective interventions, can be highly
effective in reducing the clinical attack rate by as much as 75%
[7,8]. Pre-pandemic vaccination strategies are supported by the
results obtained during the re-appearance of H1N1 in 1976/77
which afforded the opportunity for vaccine trials in naı ¨ve and
primed human subjects. In these studies, the outcome was an
improved responsiveness in primed individuals compared to naı ¨ve
individuals upon vaccination with the then newly-emerged H1N1
strain [9]. Extensive genetic characterization of HPAI H5N1
strains has elucidated the natural evolutionary relationship of these
strains, linking groups known as ‘clades’ to a common ancestor
[10]. Reciprocal cross-reactivities in heamagglutination inhibition
(HI) tests have demonstrated antigenic similarities of heamagglu-
tinin molecules (HAs) within the same genetic clade and have
distinguished representatives of different clades [10]. The efficacy
of a pre-pandemic inactivated vaccine relies on its ability to induce
an immune response that will protect against a future pandemic
influenza virus strain. Since it is not possible to predict the nature
of the pandemic virus strain, the feasibility of a pre-pandemic
vaccination strategy will largely depend on the breadth of the
immune response and protection that is induced following
administration of such a vaccine. The production of such a
candidate inactivated pre-pandemic vaccine using a viral strain
derived from a currently circulating avian H5N1 strain is being
considered an attractive strategy [11,12].
Recently, Leroux-Roels and colleagues [13] investigated the
safety and immunogenicity of an inactivated split A/Vietnam/
1194/2005 (clade 1) H5N1 pandemic candidate vaccine adju-
vanted with a proprietary oil-in-water emulsion based Adjuvant
System in healthy human adults aged 18–60 years. This study was
the first to show robust immune responses induced at low antigen
doses in association with a novel adjuvant, including the induction
of cross-clade immunity against a drifted H5N1 isolate (A/
Indonesia/5/2005, clade 2) [4,13]. This adjuvanted H5N1
candidate vaccine was well-tolerated by all trial participants [13].
As cross-protective efficacy studies of an H5N1 candidate
vaccine cannot currently be investigated in clinical trials, for
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vaccine. Here, the same inactivated split A/Vietnam/1194/2005
(clade 1) H5N1 adjuvanted vaccine was evaluated in the ferret
(Mustela putorius furo) for its potential to induce efficient cross-
protective immunity against a clade 2 drifted strain (A/Indonesia/
5/2005). Although the mouse is the most suitable animal model
for evaluation of influenza vaccine-induced antigen-specific T cell
responses, the ferret is currently accepted as the most suitable
mammalian host for efficacy studies of HPAI H5N1 vaccines
[14,15]. As recently shown by Govorkova et al. [16], the ferret
model provides the basis for developing influenza vaccines that will
be effective in the face of a contemporary influenza pandemic
threat. To ensure that immunological cross-reactivity and cross-
protection would be evaluated in sufficiently stringent conditions,
the preclinical study reported here was performed using virus
strains from different clades.
RESULTS AND DISCUSSION
Four groups of 6 ferrets were immunized intramuscularly with two
doses of 15, 7.5, 3.8 or 1.7 mg HA of inactivated split A/H5N1/
Vietnam/1194/04 NIBRG-14 (recombinant clade 1 H5N1
engineered by reverse genetics) vaccine adjuvanted with a
proprietary oil-in-water emulsion based Adjuvant System [13].
The two control groups included ferrets administered with either
the Adjuvant System alone or the non-adjuvanted A/Vietnam
vaccine (containing 15 mg HA). Ferrets were vaccinated on days 0
and 21 and challenged intratracheally on day 49 with a lethal dose
of A/Indonesia/5/2005 virus, 10
5 TCID50 (50% tissue culture
infective dose). Following the challenge with A/Indonesia all
control animals receiving adjuvant alone or non-adjuvanted A/
Vietnam vaccine died or were moribund and were euthanized on
days 3 or 4 (Table 1). In contrast, all ferrets that received two doses
of $3.8 mg of the adjuvanted A/Vietnam vaccine survived the
lethal heterologous challenge. Furthermore, all except one animal
survived the challenge in the group of ferrets who received the
lowest dose (1.7 mg HA) of the adjuvanted vaccine. Thus overall
96% of animals immunized with adjuvanted H5N1 split vaccine
were protected against the lethal challenge with A/Indonesia and
survived to the end of the challenge phase on day 5 (see Table 1).
Moribund animals showed general depression, anorexia,
lethargy and exhibited clinical signs of respiratory disease,
including dyspnea. All animals that died prematurely showed
signs of atypical pneumonia in one or more lung lobes by
macroscopic and/or microscopic analysis (data not shown).
High levels of virus replication ($10
5.5 TCID50/g tissue) were
observed in the lungs of all ferrets immunized with either the
Adjuvant System alone or with non-adjuvanted A/Vietnam
vaccine. Conversely, in 67% ferrets immunized with the
adjuvanted A/Vietnam vaccines, lung virus loads were ,10
2
TCID50/g of lung tissue (Table 1). These low virus loads were
observed in 80% and 83% of ferrets immunized with the
adjuvanted 7.5 mg and 15 mg formulations, respectively. However,
there was no overall antigen-dose dependent effect on viral load
observed among ferrets immunized with adjuvanted A/Vietnam
vaccines (Figure 1). In general high levels of virus replication in the
lung correlated with mortality. Of the animals that died all had a
lung virus load $8610
4 TCID50/g tissue, and there was only one
animal with a high viral load (1610
5 TCID50/g tissue) who
survived until the end of the experiment (day 5 post-challenge).
Both the amount of virus shed into the upper respiratory tract
and numbers of animals shedding virus were reduced in vaccinees
relative to control animals. A majority (92%) of ferrets inoculated
with the Adjuvant System alone or the non-adjuvanted A/
Vietnam vaccine shed high levels of virus (.10
2 TCID50 /ml) in
the upper respiratory tract (throat or nasal swabs) throughout the
course of infection. Conversely, only 26% ferrets receiving
adjuvanted A/Vietnam vaccines shed virus in throat or nasal
swabs and none of the ferrets immunized with the 3.8 or 7.5 mg
doses of adjuvanted A/Vietnam vaccines exhibited viral shedding
.10
2 TCID50 /ml (Table 1). Since the probability of viral
transmission would likely decrease with reduced virus shedding in
the upper respiratory tract [17,18], our data suggest a potential for
vaccination to confer a lower risk of viral transmission, a key
property in controlling pandemic virus spread within populations.
Before vaccination, ferrets used in this study were influenza
naı ¨ve as measured by an ELISA assay for the presence of
antibodies specific for nucleoprotein [19]. Post-vaccination
serological assessments showed that the adjuvanted A/Vietnam
vaccine formulations induced neutralizing antibody responses
against the homologous A/Vietnam strain with 74% of responders
(ferrets with neutralizing antibody titres . 28) compared to 100%
non responders in control groups (Table 2). Furthermore, the
adjuvanted A/Vietnam vaccine induced inter-clade cross-neutral-
izing antibody responses to the heterologous A/Indonesia clade 2
strain (Table 2) with 61% responders, while no neutralizing
antibody response (,28) was observed in ferrets immunized with
the non-adjuvanted A/Vietnam vaccine or the Adjuvant System
alone. No antigen-dose dependent effect on neutralizing antibody
titres was observed amongst ferrets immunized with adjuvanted
Table 1. Efficacy of adjuvanted split H5N1-vaccine against a heterologous H5N1 challenge in ferrets.
..................................................................................................................................................
Vaccination regimen
Dead/Total (%
survival
c) Viral load in the lung
a Viral shedding in the URT
b
Ferrets (%) with
viral load #10
2
Ferrets (%) with
viral load $10
5.5
Ferrets (%) with
viral shedding
Ferrets (%) with
viral titer $10
2
Adjuvant alone 6/6 (0) 0/6 (0) 6/6 (100) 6/6 (100) 5/6 (83)
Unadjuvanted H5N1 (15 mg) 6/6 (0) 0/6 (0) 6/6 (100) 5/6 (83) 5/6 (83)
Adjuvanted H5N1 (1.7 mg) 1/6 (83) 4/6 (67) 0/6 (0) 2/6 (33) 2/6 (33)
Adjuvanted H5N1 (3.8 mg) 0/6 (100) 3/6 (50) 0/6 (0) 1/6 (17) 0/6 (0)
Adjuvanted H5N1 (7.5 mg) 0/5 (100) 4/5 (80) 0/5 (0) 1/5 (20) 0/5 (0)
Adjuvanted H5N1 (15 mg) 0/6 (100) 5/6 (83) 0/6 (0) 2/6 (33) 2/6 (33)
aTCID50 per gram of lung tissue on Day 5 post-challenge or the day of the death
bVirus titration (TCID50 per ml of swab) in the Upper Respiratory Tract (URT) from throat and nasal swabs collected on days 2,3,4 and 5 post-challenge until day of death.
c% survival on day 5 post challenge
doi:10.1371/journal.pone.0001401.t001
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PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1401A/Vietnam vaccines. Interestingly, all animals without a detect-
able neutralizing antibody response to A/Vietnam or to A/
Indonesia exhibited lung virus load . 8610
3 TCID50/g tissue,
whereas 94% (16/17) of ferrets with anti-A/Vietnam neutralizing
antibody response and 93% (13/14) with anti-A/Indonesia
responses showed virus loads in their lungs below 10
2 TCID50/g
tissue. Of 22 animals surviving until the termination of the
experiment at day five post-challenge, 17 (77%) were positive for
the induction of an H5N1 neutralizing antibody response. Four of
the five non-responder animals that were protected from mortality
exhibited reduced virus loads in the lung relative to unvaccinated
control animals (ranging from 9610
3 to 5610
4 TCID50/g tissue),
suggesting a possible role for vaccine induced cellular immune
responses in the control of virus replication.
These results highlight the potential of this adjuvanted split H5N1
candidate vaccine to induce, even with a low dose of antigen
(3.8 mg), a strong cross-protective response in ferrets against a lethal
challenge with heterologous H5N1 virus from another genetic
sublineage and suggest that cross-protection may be mediated at
least in part by antigen-induced humoral immunity. However, we
cannot rule out a role for cell mediated immune responses in cross-
protection in the ferret model. There is evidence that cell-mediated
immune responses can be linked to protection against influenza in
humans [20,21] and it has been shown in other disease systems that
adjuvants can be effective at inducing protective cell mediated
immune responses [22–25]. As immunological reagents needed to
study T cell responses in ferrets are largely lacking, investigation of
influenza vaccine-induced antigen-specific T cell responses will be
undertaken in mouse and macaque models and in clinical studies.
Data reported in the literature and other preliminary investi-
gations (unpublished observations) suggest that multiple mecha-
nisms of action can account for the immunostimulatory properties
of the adjuvant used in this study. Indeed, in addition to their
vehicle properties, oil-in-water based emulsions have been shown
to induce local inflammation and to attract immunocompetent
cells to the injection site [26,27]. In this context, studies are
currently ongoing to elucidate the adjuvanted vaccine’s ability to
induce cell mediated immune responses.
Other published studies have similarly documented cross-clade
protection in ferrets vaccinated with different pandemic vaccine
candidates [16,28,29]. Here we document the first study in which
protection against heterologous challenge in ferrets is generated by
a candidate pandemic vaccine proven to be safe and immunogenic
in humans [13], inducing neutralizing antibodies specific for both
Table 2. Neutralizing antibody responses to the vaccine strain (A/Vietnam) and the challenge strain (A/Indonesia) 42 days after first
vaccination, i.e 21 days after second vaccination
..................................................................................................................................................
Vaccination regimen Anti-A/Vietnam neutralizing titers Anti-A/Indonesia neutralizing titers
Day 21(Post II)
a Responders
b Day 21 (Post II)
a Responders
b
GMT (95% CI) GMT (95% CI)
Adjuvant alone ,28 0/6 ,28 0/6
Unadjuvanted H5N1 (15 mg) ,28 0/6 ,28 0/6
Adjuvanted H5N1 (1.7 mg) 83 (19–371) 4/6 36 (15–83) 4/6
Adjuvanted H5N1 (3.8 mg) 113 (24–521) 4/6 43 (16–116) 4/6
Adjuvanted H5N1 (7.5 mg)
a 104 (18–602) 4/5 35 (12–107) 3/5
Adjuvanted H5N1 (15 mg) 83 (29–234) 5/6 26 (12–55) 3/6
aNeutralizing antibody GMT were ,28 before immunization (Day 0) and after first vaccination (Day 21 Post I).
bA responder is defined by neutralizing titers $ 28.
doi:10.1371/journal.pone.0001401.t002
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Figure 1. A/H5N1 viral load in the lung: Viral titres in the right lung of each animal (n=6 in each group except in the group ‘‘Adjuvanted H5N1
(7.5 mg) were n=5) were determined by means of virus titration culture on Madin-Darby canine kidney (MDCK, 30) cells. Data were expressed as log
TCID50 per gram of lung tissue6Standard Deviation.
doi:10.1371/journal.pone.0001401.g001
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virus from a distant clade. These parallel sets of encouraging data
with the same product suggest the development of a safe and
effective pre-pandemic vaccine is a realistic goal.
MATERIALS AND METHODS
The study was carried out with outbred adult female ferrets
(Mustela putorius furo: age approximately 8 months, bodyweight
0.8–1.5 kg; Schimmel, Uddel, The Netherlands) in accordance
with the institutional guidelines for care and use of laboratory
animals. The AS adjuvanted candidate vaccine used in this study
was A/H5N1, inactivated, split influenza vaccine formulated with
a proprietary oil-in-water emulsion based Adjuvant System
manufactured by GlaxoSmithKline (GSK) Biologicals, Branch of
SmithKline Beecham Pharma GmbH & Co. KG (Dresden,
Germany) [13]. The four experimental groups of ferrets
corresponded to immunization with vaccine containing four dose
levels of inactivated split A/Vietnam HA (1.7, 3.8, 7.5 or 15 mg
HA). Two control groups included ferrets administered with either
the Adjuvant System alone or the highest dose (15 mg HA) of non-
adjuvanted A/Vietnam vaccine and were. Ferrets were vaccinated
on days 0 and 21 and were then challenged by the intra tracheal
route on day 49 with a lethal dose (105 TCID50 or 50% Tissue
Culture Infective Dose) of A/Indonesia/5/05 (H5N1 clade 2). All
surviving animals were euthanized on day 54. One animal in the
experimental group vaccinated with 7.5 mg of adjuvanted vaccine
that was not challenged in compliance with protocol guidelines
was excluded from the data recording process. Viral titrations
were performed as described elsewhere [30]. Briefly, pharyngeal
and nasal swabs were collected from all animals at days 1, 2, 3, 4, 5
post-challenge; after necropsy cranioventral, craniodorsal, caudo-
ventral and caudodorsal sections of the right lung from each
animal were collected and weighed. Lung sections and individual
swabs were homogenized and resuspended in 3 ml medium and
stored at 280uC until analysis. Viral titres were determined by
means of virus titration culture on Madin-Darby canine kidney
(MDCK) cells. Data were expressed as log TCID50 per gram of
lung tissue or per ml of swabs.
Neutralizing antibodies were determined in a microneutraliza-
tion assay on thawed frozen serum samples as described previously
[13]. A serologic response corresponds to a neutralizing titre .28.
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